TipRanks Smart Value #26: Patient Value

Shrilekha Pethe on September 2, 2025

Dear Investors,

Welcome to the 26^th edition of our recently launched TipRanks Smart Value Newsletter!

This Week’s Top Value Pick: Becton Dickinson (BDX)

Becton, Dickinson and Company, also known as Becton Dickinson or BD (BDX), is a global medical technology company that develops, manufactures, and sells medical devices, instruments, and reagents designed to improve healthcare delivery. The company operates through three business segments – Medical, Life Sciences, and Interventional – offering solutions that span drug delivery, infection prevention, laboratory automation, and advanced diagnostics. With operations in more than 190 countries, BD leverages innovation, scale, and deep clinical expertise to support healthcare providers, enhance patient safety, and advance research worldwide. Its diversified earnings base rooted in recurring demand for healthcare supplies and long-term investments in diagnostics and patient care.

Medtech Evolution

Becton Dickinson traces its origins to 1897, when Maxwell Becton and Fairleigh Dickinson founded the company in New Jersey to advance medical technology through the development of reliable instruments. Its early success came from thermometers and syringes, establishing a reputation for precision and safety. In 1954, BD introduced the first disposable syringe, setting a new standard for infection control and patient care. This emphasis on essential products positioned the company as a critical supplier to hospitals and laboratories worldwide.

Throughout the 1980s and 1990s, BD expanded into diagnostics and biosciences, leveraging acquisitions and internal R&D to diversify beyond its traditional device offerings. A defining era of expansion came in the 21st century, beginning with the $12.2 billion acquisition of CareFusion in 2015, which strengthened medication management and infusion therapy capabilities while scaling its hospital automation footprint. That same year, BD acquired CRISI Medical Systems to improve IV drug delivery safety and Cellular Research to expand into single-cell analysis.

In 2016, BD sharpened its focus by carving out its Respiratory Solutions business into Vyaire Medical, a joint venture with Apax Partners, allowing it to concentrate on higher-growth categories. A year later, BD made its largest acquisition to date – a $24 billion purchase of C. R. Bard – bringing a strong portfolio in vascular access, urology, oncology, and surgical specialties. The deal materially expanded BD’s scale, earnings power, and recurring revenue base.

From 2020 to 2021, BD accelerated smaller tuck-ins aligned with medication management and procedure-adjacent technologies. It acquired the medical business assets of CUBEX and later GSL Solutions to extend Pyxis dispensing systems with cloud and RFID-enabled pharmacy automation. Other additions included Scanwell Health (at-home diagnostics), Velano Vascular (needle-free blood draw), Tepha (resorbable biomaterials), and Tissuemed (surgical sealants), deepening pipelines across care settings.

In 2022, BD simultaneously streamlined and expanded. It spun off its Diabetes Care business as Embecta, creating a pure-play diabetes company, while acquiring Parata Systems to enter high-growth pharmacy automation. That same year, it also acquired MedKeeper, enhancing cloud-based sterile compounding and medication tracking.

Connected-care ambitions advanced in 2024 with the acquisition of Edwards Lifesciences’ Critical Care business, rebranded as BD Advanced Patient Monitoring. The deal added advanced monitoring systems, decision-support software, and AI-enabled tools, strengthening BD’s perioperative and critical care presence.

Earlier in 2025, BD announced the spin-off of its Biosciences and Diagnostic Solutions units, which will merge with Waters Corporation in a ~$17.5 billion tax-efficient Reverse Morris Trust¹ expected to close by Q1 2026. BD shareholders will hold 39% of the combined company and Waters shareholders 61%, while BD will receive a $4 billion cash distribution earmarked for share repurchases and debt reduction. The transaction will sharpen BD’s profile as a medtech-focused company, with more than 90% of revenue tied to consumables, supported by innovation in biologics, digital health, AI, and women’s health.

Taken together, BD’s acquisitions and selective separations have built a more focused, higher-growth company anchored in medication management, interventional therapies, and automation, while expanding into connected monitoring. With its BD Excellence efficiency program and disciplined portfolio reshaping, BD has positioned itself for durable earnings, stronger cash flow, and an expanded global footprint.

Today, Becton Dickinson has a market capitalization of nearly $57 billion and generates trailing twelve months’ revenues of around $21 billion. The company is ranked #211 on the Fortune 500 list.

—

1-A Reverse Morris Trust (RMT) is a complex, tax-efficient financial transaction that allows a parent company to sell off unwanted assets to a third-party company by first spinning them off into a subsidiary and then merging that subsidiary with the third party.

Medtech Powerhouse

The Medical segment remains BD’s largest revenue generator, comprising nearly 53% of the company’s total revenues and anchored by a portfolio that includes peripheral intravenous catheters, vascular access technologies, and vascular care. Its Medication Management Solutions business offers infusion delivery systems, such as infusion pumps and medication compounding workflow solutions, critical to hospital and pharmacy operations.

Pharmaceutical Systems provides pre-fillable syringes and advanced injection solutions. Demand has surged with the rise of biologics, including GLP-1 therapies for diabetes and obesity. BD has signed over 70 GLP-1 biosimilar agreements, and biologics now account for half of Pharmaceutical Systems’ revenue, reflecting a decisive strategic pivot toward high-growth therapies. The 2024 acquisition of Edwards Lifesciences’ Critical Care unit, rebranded as BD Advanced Patient Monitoring (APM), added AI-enabled connected devices that strengthen BD’s foothold in critical care.

New product launches, such as the CentroVena One catheter, targeting the $500 million central line insertion market, highlight the company’s push to expand into large addressable markets with innovations that improve safety and efficiency. In the fiscal third quarter, BD Medical delivered $2.93 billion in revenue, up 14% on an FX-adjusted basis and 3.2% organically, with the growth driven by Pharmaceutical Systems unit. Pharmaceutical Systems delivered the strongest growth, while Medication Management Solutions rose mid-single digits on infusion system upgrades and contract wins. Medication Delivery Solutions posted modest gains, as robust U.S. demand for vascular access and hypodermic products was tempered by IV fluid shortages and China’s cost-cutting volume-based procurement program. The APM unit contributed $278 million in sales, up 12.9% pro forma, led by the HemoSphere Alta monitor for critical care.

The Life Sciences business segment covers Diagnostic Systems (DS), Specimen Management, and Biosciences (BDB), serving both clinical and research applications. Although segment revenue of $1.2 billion fell 1.1% in constant currency in the fiscal third quarter, performance showed signs of recovery. Strength in specimen management was offset by weakness in diagnostics and biosciences, particularly due to lower instrument demand in China and Europe. However, specialized reagents, antibodies, and assay kits marketed through BD’s Biosciences unit continue to smooth revenue streams, providing a high-margin, recurring revenue base.

Looking forward, Becton Dickinson expects Life Sciences to return to mid-single-digit-plus growth as instrument utilization improves and new launches take hold. A next-generation BACTEC platform planned for FY2026 is expected to drive replacement demand, while an FDA submission for the first HPV self-collection kit could open a new market in preventive women’s health.

Strategic Intervention

Becton Dickinson’s Interventional segment provides surgical devices, peripheral intervention solutions, and urology and critical care (UCC) products, addressing expanding markets in minimally invasive procedures and chronic disease management. Segment revenue reached $1.33 billion in FQ3, up 6.8% in constant currency, reflecting broad-based growth. Growth was driven by the Urology and Critical Care (UCC) division with revenue surge of 12% YoY.

BD’s strategy in its Interventional segment combines innovation with targeted market expansion. By advancing technologies like Phasix and PureWick (non-invasive catheter solutions) while investing in focused sales teams, BD is strengthening its competitive position and driving above-market growth in surgical and interventional care.

Underlying these segment results is BD Excellence, the company’s global lean operating system and process improvement framework. Central to the BD 2025 strategy, it emphasizes operational efficiency, quality, and continuous improvement across manufacturing, R&D, and commercial functions. To date, BD Excellence has reduced manufacturing waste by 35%, improved sustainability, and expanded output capacity by 2.5 billion units annually without major capital investment. The platform also accelerates R&D programs, optimizes commercial deployment, and strengthens supply chain resilience.

This operational rigor has proven critical in offsetting external pressures. Becton Dickinson expects $275 million in tariff costs by FY2026 from U.S.-China trade policies, but has mitigated the impact through sourcing shifts, renegotiated contracts, redesigned kits, and logistics efficiencies. Its supply chain robustness has earned industry recognition, highlighting its ability to withstand raw material shortages, logistical bottlenecks, and public health shocks.

Despite operational wins, BD faces ongoing challenges. China’s VBP programs (a government-led initiative aimed at reducing healthcare costs) continue to pressure pricing and market share. Certain categories such as vaccines and generics face volatility from competitive bidding and public health cycles. BD’s Life Sciences business, which supports research institutions and biopharma companies, has faced softer demand as U.S. and European research budgets slowed with reduced government funding and post-pandemic reallocations. These pressures curbed capital spending on advanced instruments and reagents typically tied to grants and institutional budgets. Still, the company’s strategy positions it for long-term strength. The planned separation of its Biosciences and Diagnostic Solutions units into a new entity with Waters Corporation will sharpen BD’s focus as a pure-play medtech leader. Management is targeting mid-single-digit or better organic revenue growth, with stable margins preserved through Transitional Service Agreements.

Financial Resilience

Over the past three years, Becton Dickinson has grown revenues at a 4.1% CAGR, driven by product launches, acquisitions, and solid commercial execution. However, earnings declined by 1.8% during the same period, reflecting higher operating costs and increased investments.

In the third fiscal quarter of 2025, BD delivered robust results with accelerating revenue momentum and stable margin expansion across its diversified portfolio. Total revenues reached $5.5 billion, up 8.5% on a currency-neutral adjusted basis and 3.0% organically, in line with consensus estimates. Growth was fueled by strategic investments, successful product launches, and efficiencies from the BD Excellence lean operating system, which supported gross margin gains and lifted the adjusted operating margin to 25.8%, up 60 basis points year over year. Adjusted diluted EPS rose 5.1% to $3.68, exceeding Street expectations.

At the end of Q3, BD held $819 million in cash and short-term investments, reflecting prudent liquidity management alongside international expansion. Total debt stood at $19.3 billion, including $1.8 billion in current obligations and $17.5 billion in long-term borrowings, down from nearly $20.1 billion during the same period last year. Net leverage was 2.8x, above the sector median due to acquisition funding, shareholder returns, and macroeconomic pressures, though progress continues toward the longer-term net leverage target of 2.5x. The company retains investment-grade ratings of “Baa2” from Moody’s and “BBB” from S&P and Fitch, reflecting a stable outlook.

Looking ahead, management raised full-year adjusted EPS guidance to $14.38 at the midpoint, representing 9.4% growth and above the consensus of $14.18. FY25 revenue guidance was reaffirmed at $21.85 billion at the midpoint, with organic growth of 3%–3.5%, broadly consistent with analyst estimates of $21.8 billion. BD’s outlook is underpinned by its pipeline of more than 100 new product launches by FY25, spanning connected care, molecular diagnostics, and vascular access.

Revenue growth is expected to accelerate in the fourth quarter, supported by the full organic contribution of the Advanced Patient Monitoring (APM) business, stronger BACTEC blood culture utilization following supply recovery, and easier comparatives in Diagnostic Solutions (DS). The company remains on track to meet its FY25 target of a 25% operating margin, despite external headwinds.

For fiscal 2025, BD anticipates $90 million in tariff expenses, mostly in the back half of the year. In Q4, gross margin is projected to remain flat year over year, with about 150 basis points of tariff-related costs absorbed through operational efficiencies and disciplined cost management.

Dividend Dynasty

Becton Dickinson holds a Dividend King badge, having raised its dividend for 53 consecutive years. Over the past decade, payouts have grown at an annual rate of 5.56%. For the most recent quarter, the company declared a dividend of $1.04 per share, or $4.16 annually, representing a payout ratio of about 29% of adjusted earnings. With a yield of 2.11%, BD’s dividend exceeds the healthcare sector average of 1.74%.

Strong cash generation underpins these shareholder returns. During the first nine months of fiscal 2025, BD produced $2.08 billion in net cash from operating activities, reflecting consistent earnings and solid cash conversion. Investing activities resulted in a net outflow of $324 million, largely from $408 million in capital expenditures, partially offset by inflows from maturing investments. Financing uses totaled $2.81 billion, driven by $1.2 billion in debt repayments, $899 million in dividends, and $750 million in share repurchases. Free cash flow for the year-to-date reached $1.66 billion, up by $1 billion sequentially thanks to improved collections and working capital management, which offset higher inventories and tariff payments.

Share buybacks were executed under the company’s 2021 repurchase authorization for 10 million shares with no expiration date. Earlier in 2025, the Board approved an additional 10 million share buyback program, also without expiration. BD expects to complete its $1 billion buyback commitment by September.

Despite these strong fundamentals, BDX shares have fallen about 20% over the past year amid a difficult market atmosphere for broad healthcare stocks, as well as slower-than-expected revenue growth, tariff and policy headwinds, and restructuring uncertainty, which weighed on investor sentiment. The stock now trades at meaningful discounts of over 23% below the sector median on trailing and forward P/E ratios, more than 30% below its historical averages on P/E and price-to-sales, 23% below on price-to-book, 7% below on forward EV/EBITDA, and 4% below on price-to-cash flow.

Relative to peers such as Danaher and Abbott, BD trades in a low-to-moderate valuation range across key metrics like trailing and forward P/E ratios, EV/EBITDA, price-to-book, and price-to-cash flow ratios. A discounted cash flow (DCF) analysis further supports the undervaluation thesis, suggesting the stock may be mispriced by nearly 13%.

Analysts share a constructive view, with consensus estimates pointing to roughly 3% upside, but some – like Barclays and Stiefel – project potential gains over 25% from current price levels. Bullish sentiment is supported by BD’s resilient financial performance, strong cash flow, disciplined capital allocation, innovative portfolio, and attractive valuation – factors that collectively underpin a favorable long-term outlook for shareholders.

Investing Takeaway

Becton Dickinson offers a compelling case for value-oriented investors. Despite recent share price weakness driven by tariffs, restructuring, and policy headwinds, the company’s fundamentals remain strong. With a legacy of consistent dividend growth, resilient free cash flow, and disciplined capital deployment, BD has built a stable foundation that supports long-term shareholder returns. Its diversified portfolio, spanning medication management, diagnostics, and interventional solutions, provides recurring revenue streams and exposure to high-growth areas like biologics, connected care, and women’s health. Ongoing portfolio reshaping, efficiency initiatives, and innovation investments further enhance earnings potential. Trading at a discount to both peers and historical averages, the stock reflects investor caution rather than business weakness. For patient investors, BD’s combination of reliable dividends, durable cash flows, and attractive valuation positions it as a value opportunity with upside potential as growth catalysts take hold.

Category: Smart Value